Rice Hall James & Associates LLC Sells 26,887 Shares of Evolus, Inc. (NASDAQ:EOLS)

Rice Hall James & Associates LLC reduced its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 2.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 921,394 shares of the company's stock after selling 26,887 shares during the period. Rice Hall James & Associates LLC owned about 1.45% of Evolus worth $11,084,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in EOLS. Assenagon Asset Management S.A. raised its holdings in shares of Evolus by 63.2% during the first quarter. Assenagon Asset Management S.A. now owns 710,713 shares of the company's stock worth $8,550,000 after purchasing an additional 275,260 shares during the period. Rhumbline Advisers grew its position in shares of Evolus by 4.1% during the first quarter. Rhumbline Advisers now owns 83,436 shares of the company's stock worth $1,004,000 after acquiring an additional 3,287 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Evolus by 1,765.9% during the first quarter. GAMMA Investing LLC now owns 18,622 shares of the company's stock worth $224,000 after acquiring an additional 17,624 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of Evolus during the fourth quarter worth about $753,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Evolus by 6.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,052 shares of the company's stock valued at $1,270,000 after buying an additional 6,821 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EOLS. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Finally, BTIG Research began coverage on shares of Evolus in a research report on Thursday, April 17th. They issued a "buy" rating and a $21.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $23.75.

Evolus Stock Performance

EOLS stock traded up $0.14 during midday trading on Thursday, hitting $9.34. 534,691 shares of the company traded hands, compared to its average volume of 769,536. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The company has a quick ratio of 2.16, a current ratio of 2.34 and a debt-to-equity ratio of 22.00. The business has a 50 day simple moving average of $9.59 and a 200-day simple moving average of $11.36. The stock has a market capitalization of $602.24 million, a price-to-earnings ratio of -10.49 and a beta of 0.97.

Insider Activity at Evolus

In related news, Director Albert G. White III acquired 20,000 shares of the stock in a transaction dated Monday, June 9th. The shares were acquired at an average price of $9.45 per share, for a total transaction of $189,000.00. Following the completion of the purchase, the director owned 50,378 shares in the company, valued at approximately $476,072.10. The trade was a 65.84% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Sandra Beaver sold 6,494 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total transaction of $65,069.88. Following the completion of the sale, the chief financial officer owned 167,089 shares in the company, valued at approximately $1,674,231.78. The trade was a 3.74% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 153,571 shares of company stock worth $1,537,090. Insiders own 5.90% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.